Traditional MedicareCoverageHigh impact
MolDx: Molecular Testing for Solid Organ Allograft Rejection
Medicare/CMS - LCD·Transplant Surgery, Nephrology·Local Coverage Determination
We identified it
Sep 3, 2026
Summary
This policy (L38680) for MolDx molecular testing related to solid organ allograft rejection has been RETIRED as of 8/29/2026. This is a policy termination, not a new coverage addition. The practice must immediately stop applying this local coverage determination and verify current coverage guidance from WPS Insurance Corporation (MAC Part A/B) or use national Medicare policies.
Action Required
Immediately: Billing team must STOP using LCD L38680 for molecular testing claims related to solid organ allograft rejection. Verify current coverage status with WPS Insurance Corporation (MAC Part A and Part B contractor) before billing any MolDx or similar molecular testing for transplant rejection. Update billing system rules, templates, and prior authorization protocols to remove references to this retired policy. Contact WPS directly for replacement policy guidance or applicable national Medicare coverage. Failure to identify the current applicable policy may result in claim denials or improper reimbursement.